Intraocular penetration of cytosine arabinoside following subconjunctival administration in primates

M. L. Graham, W. E. Smiddy, William E Smiddy, A. P. Schachat

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cytosine arabinoside was administered subconjunctivally to three monkeys. Blood, aqueous, and vitreous specimens were collected after 30 minutes, 1 hour, 2 hours, and 3 hours. Intraocular drug concentrations appeared stable or increasing over this time period while intravenous levels were relatively low. The results of this study suggest that therapeutic intraocular concentrations of cytosine arabinoside are obtained following subconjunctival administration in primates with lower, nontoxic intravenous levels during this time.

Original languageEnglish
Pages (from-to)255-259
Number of pages5
JournalJournal of Ocular Pharmacology
Volume5
Issue number3
StatePublished - Dec 1 1989

Fingerprint

Cytarabine
Primates
Haplorhini
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Intraocular penetration of cytosine arabinoside following subconjunctival administration in primates. / Graham, M. L.; Smiddy, W. E.; Smiddy, William E; Schachat, A. P.

In: Journal of Ocular Pharmacology, Vol. 5, No. 3, 01.12.1989, p. 255-259.

Research output: Contribution to journalArticle

@article{865a673449c84487a68b4cdda76de860,
title = "Intraocular penetration of cytosine arabinoside following subconjunctival administration in primates",
abstract = "Cytosine arabinoside was administered subconjunctivally to three monkeys. Blood, aqueous, and vitreous specimens were collected after 30 minutes, 1 hour, 2 hours, and 3 hours. Intraocular drug concentrations appeared stable or increasing over this time period while intravenous levels were relatively low. The results of this study suggest that therapeutic intraocular concentrations of cytosine arabinoside are obtained following subconjunctival administration in primates with lower, nontoxic intravenous levels during this time.",
author = "Graham, {M. L.} and Smiddy, {W. E.} and Smiddy, {William E} and Schachat, {A. P.}",
year = "1989",
month = "12",
day = "1",
language = "English",
volume = "5",
pages = "255--259",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Intraocular penetration of cytosine arabinoside following subconjunctival administration in primates

AU - Graham, M. L.

AU - Smiddy, W. E.

AU - Smiddy, William E

AU - Schachat, A. P.

PY - 1989/12/1

Y1 - 1989/12/1

N2 - Cytosine arabinoside was administered subconjunctivally to three monkeys. Blood, aqueous, and vitreous specimens were collected after 30 minutes, 1 hour, 2 hours, and 3 hours. Intraocular drug concentrations appeared stable or increasing over this time period while intravenous levels were relatively low. The results of this study suggest that therapeutic intraocular concentrations of cytosine arabinoside are obtained following subconjunctival administration in primates with lower, nontoxic intravenous levels during this time.

AB - Cytosine arabinoside was administered subconjunctivally to three monkeys. Blood, aqueous, and vitreous specimens were collected after 30 minutes, 1 hour, 2 hours, and 3 hours. Intraocular drug concentrations appeared stable or increasing over this time period while intravenous levels were relatively low. The results of this study suggest that therapeutic intraocular concentrations of cytosine arabinoside are obtained following subconjunctival administration in primates with lower, nontoxic intravenous levels during this time.

UR - http://www.scopus.com/inward/record.url?scp=0024820250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024820250&partnerID=8YFLogxK

M3 - Article

C2 - 2625619

AN - SCOPUS:0024820250

VL - 5

SP - 255

EP - 259

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 3

ER -